Optimal antihypertensive level for improvement of coronary microvascular dysfunction: The lower, the better?

Hypertension

Volumn 60, Issue 2, 2012, Pages 326-332

  Mizuno, Reiko ^a   Fujimoto, Shinichi ^a   Saito, Yoshihiko ^a   Okamoto, Yasuyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

antihypertensive treatment; blood pressure; coronary microvascular dysfunction; echocardiography; hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY FLOW RESERVE; CORONARY MICROVASCULAR DYSFUNCTION; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MICROANGIOPATHY; PREHYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HEMODYNAMICS; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MICROVESSELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREHYPERTENSION; REGIONAL BLOOD FLOW;

EID: 84864289304     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.189209     Document Type: Article

References (29)

1. Antony I, Nitenberg A, Foult JM, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol. 1993;22:514-520. (Pubitemid 23214566)
2. Erdogan D, Yildirim I, Ciftci O, Ozer I, Caliskan M, Gullu H, et al. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation. 2007;115:593-599. (Pubitemid 46226169)
3. Parodi O, Neglia D, Palombo C, Sambuceti G, Giorgetti A, Marabotti C, et al. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation. 1997;96:864-873. (Pubitemid 27329621)
4. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: A comparison of lisinopril and losartan. J Am Coll Cardiol. 2002;40: 703-709. (Pubitemid 34925617)
5. Tomás JP, Moya JL, Barrios V, Campuzano R, Guzman G, Megías A, et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens. 2006;24:2109-2114. (Pubitemid 44371279)
6. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow reserve: measurement with transthoracic Doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol. 2001;21:114-122.
7. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19: 1550-1558.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108. (Pubitemid 43257193)
10. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618. (Pubitemid 8066109)
11. Erdogan D, Gullu H, Caliskan M, Yildirim I, Tok D, Muderrisoglu H. Coronary flow reserve is preserved in white-coat hypertension. Heart. 2006;92:1109-1112. (Pubitemid 44125230)
12. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension. 1996;27:1031-1038. (Pubitemid 26140657)
13. Buus NH, Bøttcher M, Jørgensen CG, Christensen KL, Thygesen K, Nielsen TT, et al. Myocardial perfusion during long-term angiotensinconverting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension. 2004;44:465-470. (Pubitemid 39281497)
14. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25: 474-481.
15. Kozàkovà M, Palombo C, Pratali L, Pittella G, Galetta F, L'Abbate A. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography. Hypertension. 1997;29:551-559. (Pubitemid 27074717)
16. Brush JE Jr, Cannon RO 3rd, Schenke WH, Bonow RO, Leon MB, Maron BJ, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319: 1302-1307. (Pubitemid 19003391)
17. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993;87:86-93. (Pubitemid 23019338)
18. Galderisi M, Cicala S, Caso P, De Simone L, D'Errico A, Petrocelli A, et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol. 2002;90:860-864.
19. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88: 993-1003. (Pubitemid 23264015)
20. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994;90:808-817. (Pubitemid 24242749)
21. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833-838. (Pubitemid 44175741)
22. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472. (Pubitemid 41124179)
23. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke. 2005;36: 1859-1863. (Pubitemid 41266514)
24. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol. 1989;257:H1110-H1118.
25. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
26. Farhi ER, Klocke FJ, Mates RE, Kumar K, Judd RM, Canty JM Jr, et al. Tone-dependent waterfall behavior during venous pressure elevation in isolated canine hearts. Circ Res. 1991;68:392-401.
27. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-893. (Pubitemid 46768128)
28. Messerli FH, Kupfer S, Pepine CJ. J curve in hypertension and coronary artery disease. Am J Cardiol. 2005;95:160. (Pubitemid 40051140)
29. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27: 1360-1369.